The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - AstraZeneca; Chugai Foundation for Innovative Drug Discovery Science; Johnson & Johnson/MedTech; Lilly; Medtronic; Ono Pharmaceutical
Five-year survival outcomes from the PIT-1 trial: Pemetrexed-cisplatin plus bevacizumab or concurrent thoracic radiation therapy followed by surgery in stage IIIA (N2) nonsquamous non-small cell lung cancer.
 
Kazuya Takamochi
No Relationships to Disclose
 
Kenji Suzuki
No Relationships to Disclose
 
Masahiro Tsuboi
No Relationships to Disclose
 
Seiji Niho
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Satoshi Ishikura
Honoraria - AstraZeneca
 
Shunsuke Oyamada
Honoraria - Chugai Pharma
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Clinical Trial; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EPS Corporation; Incyte; intellim; Japan Tobacco Inc; Kowa; Merck; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Public Health Research Foundation; Seikagaku; Sonire Therapeutics
Speakers' Bureau - 3H Clinical Trial; Medical Mobile Communications co., Ltd.; Merck
Research Funding - 3H Clinical Trial (Inst); 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice (Inst); Cordis. (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Eisai (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Kirin Co., Ltd.; Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Puravida Technologies (Inst); Senju Pharmaceutical (Inst); Solasia Pharma (I); TSUMURA & CO. (Inst); Welby (Inst)
 
Hidemi Suzuki
No Relationships to Disclose
 
Hiroyuki Ito
No Relationships to Disclose
 
Norihito Okumura
No Relationships to Disclose
 
Fumihiro Tanaka
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Intuitive Japan; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly Japan; MSD; Olympus Medical Systems; Ono Pharmaceutical; Pfizer; Stryker; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hisashi Saji
No Relationships to Disclose
 
Terumoto Koike
No Relationships to Disclose
 
Hirotoshi Horio
No Relationships to Disclose
 
Makoto Endo
No Relationships to Disclose
 
Toshiya Fujiwara
No Relationships to Disclose
 
Norihiko Ikeda
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)